|
1
|
Xu YJ, Du Y and Fan Y: Long noncoding RNAs
in lung cancer: What we know in 2015. Clin Transl Oncol.
18:660–665. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang HH, Pang M, Dong W, Xin JX, Li YJ,
Zhang ZC, Yu L, Wang PY, Li BS and Xie SY: miR-511 induces the
apoptosis of radioresistant lung adenocarcinoma cells by triggering
BAX. Oncol Rep. 31:1473–1479. 2014.PubMed/NCBI
|
|
4
|
Ma Y, Li X, Cheng S, Wei W and Li Y:
MicroRNA-106a confers cisplatin resistance in non-small cell lung
cancer A549 cells by targeting adenosine triphosphatase-binding
cassette A1. Mol Med Rep. 11:625–32. 2015.PubMed/NCBI
|
|
5
|
Saito M, Shiraishi K, Matsumoto K,
Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, Nokihara H,
Watanabe S, Tsuta K, et al: A three-microRNA signature predicts
responses to platinum-based doublet chemotherapy in patients with
lung adenocarcinoma. Clin Cancer Res. 20:4784–4793. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rinn JL and Chang HY: Genome regulation by
long noncoding RNAs. Annu Rev Biochem. 81:145–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guttman M, Amit I, Garber M, French C, Lin
MF, Feldser D, Huarte M, Zuk O, Carey BW and Cassady JP: Chromatin
signature reveals over a thousand highly conserved large non-coding
RNAs in mammals. Nature. 458:223–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huarte M and Rinn JL: Large non-coding
RNAs: Missing links in cancer? Hum Mol Genet. 19:R152–R161. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsai MC, Spitale RC and Chang HY: Long
intergenic noncoding RNAs: New links in cancer progression. Cancer
Res. 71:3–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang F, Yuan JH, Wang SB, Yang F, Yuan SX,
Ye C, Yang N, Zhou WP, Li WL, Li W and Sun SH: Oncofetal long
noncoding RNA PVT1 promotes proliferation and stem cell-like
property of hepatocellular carcinoma cells by stabilizing NOP2.
Hepatology. 60:1278–1290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ,
Tao QF, Liu F, Pan W, Wang TT, Zhou CC, et al: A Long Noncoding RNA
Activated by TGF-β Promotes the Invasion-Metastasis Cascade in
Hepatocellular Carcinoma. Cancer Cell. 25:666–681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren
Y, Wu Y, Mei M, Zhang L and Wang X: Long non coding RNA MALAT1
promotes tumor growth and metastasis by inducing
epithelial-mesenchymal transition in oral squamous cell carcinoma.
Sci Rep. 5:159722015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun M, Liu XH, Wang KM, Nie FQ, Kong R,
Yang JS, Xia R, Xu TP, Jin FY, Liu ZJ, et al: Downregulation of
BRAF activated non-coding RNA is associated with poor prognosis for
non-small cell lung cancer and promotes metastasis by affecting
epithelial-mesenchymal transition. Mol Cancer. 13:682014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nowacki S, Skowron M, Oberthuer A, Fagin
A, Voth H, Brors B, Westermann F, Eggert A, Hero B, Berthold F and
Fischer M: Expression of the tumour suppressor gene CADM1 is
associated with favourable outcome and inhibits cell survival in
neuroblastoma. Oncogene. 27:3329–3338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fischer M, Oberthuer A, Brors B, Kahlert
Y, Skowron M, Voth H, Westermann F, Eggert A, Hero B, Berthold F
and Fischer M: Differential expression of neuronal genes defines
subtypes of disseminated neuroblastoma with favorable and
unfavorable outcome. Clin Cancer Res. 12:5118–5128. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Watabe K, Ito A, Koma YI and Kitamura Y:
IGSF4: A new intercellular adhesion molecule that is called by
three names, TSLC1, SgIGSF and SynCAM, by virtue of its diverse
function. Histol Histopathol. 18:1321–1329. 2003.PubMed/NCBI
|
|
19
|
Lung HL, Cheung AK, Xie D, Cheng Y, Kwong
FM, Murakami Y, Guan XY, Sham JS, Chua D, Protopopov AI, et al:
TSLC1 is a tumor suppressor gene associated with metastasis in
nasopharyngeal carcinoma. Cancer Res. 66:9385–9392. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heller G, Geradts J, Ziegler B, Newsham I,
Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer
W, Depisch D, et al: Downregulation of TSLC1 and DAL-1 expression
occurs frequently in breast cancer. Breast Cancer Res Treat.
103:283–291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Honda T, Tamura G, Waki T, Jin Z, Sato K,
Motoyama T, Kawata S, Kimura W, Nishizuka S and Murakami Y:
Hypermethylation of the TSLC1 gene promoter in primary gastric
cancers and gastric cancer cell lines. Jpn J Cancer Res.
93:857–860. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jansen M, Fukushima N, Rosty C, Walter K,
Altink R, Heek TV, Heek TV, Hruban R, Offerhaus JG and Goggins M:
Aberrant methylation of the 5-CpG island of TSLC1 is common in
pancreatic ductal adenocarcinoma and is first manifest in
high-grade PanlNs. Cancer Biol Ther. 1:293–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen K, Wang G, Peng L, Liu S, Fu X, Zhou
Y, Yu H, Li A, Li J, Zhang S, et al: CADM1/TSLC1 inactivation by
promoter hypermethylation is a frequent event in colorectal
carcinogenesis and correlates with late stages of the disease. Int
J Cancer. 128:266–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang YX, Yang AH, Yang ZJ, Wang ZR and Xia
XH: Involvement of tumor suppressor in lung cancer 1 gene
expression in cervical carcinogenesis. Int J Gynecol Cancer.
16:1868–1872. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Williams YN, Masuda M, Sakurai-Yageta M,
Maruyama T, Shibuya M and Murakami Y: Cell adhesion and prostate
tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin
superfamily molecule homologous to TSLC1/IGSF4. Oncogene.
25:1446–1453. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kuramochi M, Fukuhara H, Nobukuni T, Kanbe
T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura
T, et al: TSLC1 is a tumor suppressor gene in human non-small cell
lung cancer. Nat Genet. 27:427–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nguyen-Ngoc T, Bouchaab H, Adjei AA and
Peters S: BRAF alterations as therapeutic targets in non-small-cell
lung cancer. J Thorac Oncol. 10:1396–1403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng LL, Shao YX, Lv HF, Deng HB and Lv
FZ: Over-expressing CYLD augments antitumor activity of TRAIL by
inhibiting the NF-κB survival signaling in lung cancer cells.
Neoplasma. 59:18–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo S, Tan L, Pu WL, Wu J, Xu K, Wu J, Li
Q, Ma Y, Xu J, Jin L and Wang J: Quantitative assessment of the
diagnostic role of APC promoter methylation in non-small cell lung
cancer. Clin Epigenetics. 6:52014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qin X, Yao J, Geng P, Fu X, Xue J and
Zhang Z: LncRNA TSLC1-AS1 is a novel tumor suppressor of glioma.
Int J Clin Exp Pathol. 7:3065–3072. 2014.PubMed/NCBI
|
|
31
|
Wahlestedt C: Natural antisense and
noncoding RNA transcripts as potential drug targets. Drug Discov
Today. 11:503–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Faghihi MA and Wahlestedt C: Regulatory
roles of natural antisense transcripts. Nat Rev Mol Cell Biol.
1:637–643. 2009. View
Article : Google Scholar
|
|
33
|
Yelin R, Dahary D, Sorek R, Levanon EY,
Goldstein O, Shoshan A, Diber A, Biton S, Tamir Y, Khosravi R, et
al: Widespread occurrence of antisense transcription in the human
genome. Nat Biotechnol. 21:379–386. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thrash-Bingham CA and Tartof KD: aHIF: A
natural antisense transcript overexpressed in human renal cancer
and during hypoxia. J Natl Cancer Inst. 91:143–151. 1999.
View Article : Google Scholar : PubMed/NCBI
|
